Maneesh Sud1, Navdeep Tangri2, Melania Pintilie3, Andrew S Levey4, David M J Naimark5. 1. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 2. Division of Nephrology, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Department of Biostatistics, University Health Network, Toronto, Ontario, Canada Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 4. Division of Nephrology, Tufts Medical Centre, Boston, MA, USA. 5. Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada Institute of Health Policy Management and Evaluation, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Chronic kidney disease (CKD) Stage 4 is on the path to kidney failure, but there is little information on the risks associated with progression to Stage 4 per se. The objective of this study is to determine how progression from Stage 3 to Stage 4 CKD alters morbidity and mortality in a referred cohort of patients. METHODS: We conducted a retrospective cohort study consisting of 1607 patients with estimated glomerular filtration rate (eGFR) of 30-59 mL/min/1.73 m(2) referred to a nephrologist at a tertiary care center in Ontario, Canada, between January 2001 and December 2008. Interim progression from Stage 3 to Stage 4 chronic kidney disease was defined by two independent outpatient eGFR values <30 mL/min/1.73 m(2). Death, acute kidney injury (AKI) and all-cause hospitalizations subsequent to Stage 4 progression, but prior to the development of end-stage renal disease (ESRD), ascertained from administrative databases. RESULTS: The mean (standard deviation) baseline eGFR was 43 (8) mL/min/1.73 m(2). Over 2.66 years (interquartile range: 1.42-4.45), 344 (21%) patients progressed to Stage 4, 47 (3%) developed ESRD, 188 (12%) patients died, 143 (9%) were hospitalized with AKI and 688 (43%) were hospitalized for any reason. Compared with patients who did not progress to Stage 4, those who did progress had significantly higher adjusted risks of death [hazard ratio (HR) = 2.56, 95% confidence interval (95% CI): 1.75-3.75], AKI (HR = 2.32, 95% CI: 1.44-3.74) and all-cause hospitalization (HR = 1.87, 95% CI: 1.45-2.42). CONCLUSIONS: Progression from Stage 3 to Stage 4 CKD is associated with increased risks of death, AKI and hospitalization prior to ESRD.
BACKGROUND:Chronic kidney disease (CKD) Stage 4 is on the path to kidney failure, but there is little information on the risks associated with progression to Stage 4 per se. The objective of this study is to determine how progression from Stage 3 to Stage 4 CKD alters morbidity and mortality in a referred cohort of patients. METHODS: We conducted a retrospective cohort study consisting of 1607 patients with estimated glomerular filtration rate (eGFR) of 30-59 mL/min/1.73 m(2) referred to a nephrologist at a tertiary care center in Ontario, Canada, between January 2001 and December 2008. Interim progression from Stage 3 to Stage 4 chronic kidney disease was defined by two independent outpatient eGFR values <30 mL/min/1.73 m(2). Death, acute kidney injury (AKI) and all-cause hospitalizations subsequent to Stage 4 progression, but prior to the development of end-stage renal disease (ESRD), ascertained from administrative databases. RESULTS: The mean (standard deviation) baseline eGFR was 43 (8) mL/min/1.73 m(2). Over 2.66 years (interquartile range: 1.42-4.45), 344 (21%) patients progressed to Stage 4, 47 (3%) developed ESRD, 188 (12%) patients died, 143 (9%) were hospitalized with AKI and 688 (43%) were hospitalized for any reason. Compared with patients who did not progress to Stage 4, those who did progress had significantly higher adjusted risks of death [hazard ratio (HR) = 2.56, 95% confidence interval (95% CI): 1.75-3.75], AKI (HR = 2.32, 95% CI: 1.44-3.74) and all-cause hospitalization (HR = 1.87, 95% CI: 1.45-2.42). CONCLUSIONS: Progression from Stage 3 to Stage 4 CKD is associated with increased risks of death, AKI and hospitalization prior to ESRD.
Authors: Radica Z Alicic; Robert A Short; Cynthia L Corbett; Joshua J Neumiller; Brian J Gates; Kenn B Daratha; Celestina Barbosa-Leiker; Sterling McPherson; Naomi S Chaytor; Brad P Dieter; Stephen M Setter; Katherine R Tuttle Journal: Am J Nephrol Date: 2016-08-04 Impact factor: 3.754
Authors: Yi-An Ko; Huiguang Yi; Chengxiang Qiu; Shizheng Huang; Jihwan Park; Nora Ledo; Anna Köttgen; Hongzhe Li; Daniel J Rader; Michael A Pack; Christopher D Brown; Katalin Susztak Journal: Am J Hum Genet Date: 2017-06-01 Impact factor: 11.025
Authors: Wendy McCallum; Hocine Tighiouart; Jeffrey M Testani; Matthew Griffin; Marvin A Konstam; James E Udelson; Mark J Sarnak Journal: Kidney Int Rep Date: 2020-07-23
Authors: Pasquale Cocchiaro; Valeria De Pasquale; Rossella Della Morte; Simona Tafuri; Luigi Avallone; Anne Pizard; Anna Moles; Luigi Michele Pavone Journal: Front Cell Dev Biol Date: 2017-12-19
Authors: Chengxiang Qiu; Shizheng Huang; Jihwan Park; YoSon Park; Yi-An Ko; Matthew J Seasock; Joshua S Bryer; Xiang-Xi Xu; Wen-Chao Song; Matthew Palmer; Jon Hill; Paolo Guarnieri; Julie Hawkins; Carine M Boustany-Kari; Steven S Pullen; Christopher D Brown; Katalin Susztak Journal: Nat Med Date: 2018-10-01 Impact factor: 53.440
Authors: Rani Nannan Panday; Yentl Haan; Frederieke Diemer; Amar Punwasi; Chantal Rommy; Ingrid Heerenveen; Gert A van Montfrans; Lizzy M Brewster Journal: Intern Emerg Med Date: 2018-10-26 Impact factor: 3.397